NeurogesX News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

In addition, Zacks Equity Research pro... WOLLONGONG, Australia-- --The Andrew Solutions facility in Wollongong, New South Wales - which has developed innovative location technology for commercial and emergency services appl... CHICAGO-- --Four free stock picks are being made available today on Zacks.com. The industry's leading independent research ...

In what one SF Business Times staffer called NeurogesX Inc.a s a oeshingles smackdown,a the San Mateo company won approval Monday of its Qutenza patch for shingles-related pain.

Zacks Equity Research highlights NeurogesX as the Bull of the Day and Sears Holdings the Bear of the Day.

Featured Article Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Neurology / Neuroscience ; Dermatology ; Seniors / Aging Article Date: 18 Nov 2009 - 11:00 PST The US Food and Drug Administration announced yesterday that it has approved Qutenza 8% patch for the treatment of post-herpetic neuralgia , an often excruciating ...

Shares of biotechnology company NeurogesX Inc. jumped Tuesday after the company received Food and Drug Administration approval for its Qutenza pain patch.

NeurogesX To Hold Conference Call To Discuss FDA Approval Of Qutenza 8% Patch For Treatment Of Postherpetic Neuralgia Main Category: Pain / Anesthetics Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials NeurogesX, Inc.

NeurogesX, Inc. announced today that the U.S. Food and Drug Administration has approved Qutenza 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia , the nerve pain which can follow shingles.

Biotechnology company NeurogesX Inc. said Monday it received Food and Drug Administration approval for its Qutenza pain patch.

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the expansion of its U.S. commercial operations team to include a Vice President of Sales, Senior Director of Marketing and Director of Commercial Operations.

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, November 6, 2009 at 9:00 a.m. ET to report results for its third quarter 2009.

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act date from August 16, 2009 to November 16, 2009 to review the new drug application for Qutenza to manage pain ...

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act date from August 16, 2009 to November 16, 2009 to review the new drug application for Qutenza to manage pain ...

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act date from August 16, 2009 to November 16, 2009 to review the new drug application for Qutenza to manage pain ...

NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration has extended the Prescription Drug User Fee Act date from August 16, 2009 to November 16, 2009 to review the new drug application for Qutenza to manage pain ...

NeurogesX, Inc. announced today the preliminary results of a short-term clinical study of Qutenza in patients with postherpetic neuralgia following pretreatment with an FDA-approved topical anesthetic.

NeurogesX, Inc. announced today that Bruce A. Peacock has resigned from his roles as Audit Committee chairman and director to focus on his responsibilities as CEO of privately-held Alba Therapeutics.

NeurogesX Inc. , which won approval from European regulators for its pain patch and then a partnership with Astellas Pharma, got notice from the Nasdaq market that it doesn't comply with the exchange's rules following the resignation of a key director.

NeurogesX Inc. has been added to the broad-market Russell 3000 and small-cap Russell 2000 indices.

With the PDUFA date for its capsaicin pain patch Qutenza rapidly approaching, NeurogesX Inc.